Kymera Therapeutics, Inc. (NASDAQ: KYMR) saw its stock price surge 9.33% in pre-market trading on Friday, following the release of better-than-expected first-quarter earnings and the announcement of a new drug program.
The biopharmaceutical company reported a quarterly loss of $0.82 per share, outperforming analyst estimates of a $0.92 loss. Collaboration revenue for the quarter came in at $22.10 million, more than doubling the consensus estimate of $10.15 million and representing a 114.83% increase from the same period last year.
Adding to the positive sentiment, Kymera unveiled a new first-in-class, oral IRF5 degrader program with potential applications in multiple immuno-inflammatory diseases. The company also reported that its cash position as of March 31 now provides an extended runway into the first half of 2028, alleviating potential near-term funding concerns. However, investors should note that Kymera made a strategic decision not to advance its KT-295 (Tyk2) program into further clinical development. On a forward-looking note, the company announced that KT-579 IND-enabling studies are ongoing, with Phase 1 testing expected to begin in early 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.